Dr. Zannad is Professor of Therapeutics at the University of Lorraine, Head of the Division of Heart Failure, Hypertension and Preventive Cardiology, and Director of the INSERM Clinical Investigation Centre at Institut Lorrain du Coeur et des Vaisseaux, Nancy, France. He is a cardiologist and heart failure (HF) specialist, and after researching clinical pharmacology at the University of Oxford (UK), he went on to complete a PhD in clinical pharmacology (Lyons, France). Dr. Zannad has pioneered and made significant contributions to biomarker research and evidence-based therapy for HF (mainly mineralocorticoid receptor antagonists and beta-blockers), as well in for major comorbid diseases in HF, such as sleep-disordered breathing, autonomic nervous dysfunction, diabetes, hyperkalaemia, chronic kidney disease and thrombosis. He currently leads two EU, FP7-granted programs, and he is the principal investigator (PI) of the first non-VKA oral anticoagulant outcome trial in heart failure (COMMANDER HF) and co-PI of the first glucose lowering SGLT2 inhibitor (EMPEROR HF) outcome trial in heart failure.

​ 

Dr. Zannad has served as Chairman of the French Society of Hypertension, Chairman of the European Society of Cardiology (ESC) Working Group on Pharmacology and Drug Therapy and is a board member of the Heart Failure Association (HFA) of the ESC. He is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international think tank dedicated to the science of clinical trials, with meetings in Paris and Washington DC, and in the Middle East and Asia. Dr. Zannad has had more than 660 peer-reviewed papers published, and several books and book chapters. He received the 2014 European Society of Hypertension Paul Milliez Award, and the 2017 Lifetime Achievement Award from the HFA of the ESC.